FDA review finds no link between Singulair, suicide risk

01/13/2009 | Bloomberg

An updated FDA review found that Merck & Co.'s Singulair is not tied to a higher risk of suicide, but the agency said it is still looking into other psychiatric adverse reactions associated with the asthma drug. Merck said it "stands by the proven efficacy and safety of Singulair" and that data support the medicine's continued use.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA